Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Shares Outstanding (Diluted Average) (2023 - 2025)

Zenas BioPharma has reported Shares Outstanding (Diluted Average) over the past 3 years, most recently at $44.7 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $44.7 million for Q4 2025, up 238.89% from a year ago — trailing twelve months through Dec 2025 was $44.7 million (up 238.89% YoY), and the annual figure for FY2025 was $44.7 million, up 238.89%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $44.7 million at Zenas BioPharma, up from $42.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for ZBIO hit a ceiling of $44.7 million in Q4 2025 and a floor of $1.5 million in Q4 2023.
  • Median Shares Outstanding (Diluted Average) over the past 3 years was $13.2 million (2024), compared with a mean of $21.8 million.
  • Peak annual rise in Shares Outstanding (Diluted Average) hit 2589.73% in 2025, while the deepest fall reached 238.89% in 2025.
  • Zenas BioPharma's Shares Outstanding (Diluted Average) stood at $1.5 million in 2023, then soared by 762.01% to $13.2 million in 2024, then surged by 238.89% to $44.7 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $44.7 million (Q4 2025), $42.2 million (Q3 2025), and $41.9 million (Q2 2025) per Business Quant data.